Study Results
Results pending
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
Recruitment Status
RECRUITING
Total Enrollment
100 participants
Study Classification
OBSERVATIONAL
Study Start Date
2022-06-06
Study Completion Date
2024-09-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Ferritin is a ubiquitous protein capable of storing iron in the cell cytosol. Stored iron is released and made available for cellular needs by the degradation of ferritin itself. Small amounts of ferritin are present in the blood and consist of ferritin L, a glycosylated form of L called ferritin G, and trace amounts of ferritin H. It is secreted mainly by macrophages, hepatocytes, and lymphoid cells, but most aspects of its secretion remain not fully elucidated. Serum ferritin has broad clinical utility primarily as an indicator of iron stores, so low values of serum ferritin are indicative of a deficient state and high values of iron overload. However, the causes of increased serum ferritin are numerous, in many cases serum ferritin is increased disproportionately to iron stores such as in acute and chronic liver disease, infectious and inflammatory states, metabolic disorders, and high alcohol intake that are frequently observed in the clinical setting. Therefore, the diagnosis of hyperferritinemia requires a careful strategy including personal and family history, biochemical, instrumental, and targeted genetic testing. In fact, there are rare forms of genetically determined hyperferritinemia not associated with iron overload, such as hereditary cataract hyperferritinemia syndrome (HHCS) due to mutations in the Iron responsive Element (IRE) located in the 5' untranslated region of the FTL gene. More recently, a second dominant form of genetic hyperferritinemia without iron overload or cataract (benign hyperferritinemia) has been identified.
Preliminary results obtained so far have made it possible, through WES analysis, to identify the involvement of the STAB1 gene, which was found to be mutated in the studied subjects in whom reduced serum ferritin glycosylation and reduced plasma concentration of the protein itself were observed. It is therefore deemed necessary to proceed with the assay of glycosylated ferritin and the protein encoded by the gene to assess its sensitivity and specificity as a predictive test before performing the genetic analysis of STAB1. To achieve this goal, patients with undefined hyperferritinemia afferent to the SSD Rare Diseases of the IRCCS San Gerardo Foundation in whom to perform glycosylated ferritin and STAB1 protein assay in parallel with STAB1 sequencing will be evaluated. Similar investigations will be performed in a control group consisting of cases of hyperferritinemia due to genetically determined iron overload.
Preliminary results obtained so far have made it possible, through WES analysis, to identify the involvement of the STAB1 gene, which was found to be mutated in the studied subjects in whom reduced serum ferritin glycosylation and reduced plasma concentration of the protein itself were observed. It is therefore deemed necessary to proceed with the assay of glycosylated ferritin and the protein encoded by the gene to assess its sensitivity and specificity as a predictive test before performing the genetic analysis of STAB1. To achieve this goal, patients with undefined hyperferritinemia afferent to the SSD Rare Diseases of the IRCCS San Gerardo Foundation in whom to perform glycosylated ferritin and STAB1 protein assay in parallel with STAB1 sequencing will be evaluated. Similar investigations will be performed in a control group consisting of cases of hyperferritinemia due to genetically determined iron overload.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
HEPFER-Evaluation of a New Phenotypic Biological Marker in Genetic Type 1 Hemochromatosis
NCT01784939
Hereditary Hemochromatosis C282Y Homozygous
COMPLETED
Statistical Basis for Hemochromatosis Screening
NCT00005559
Blood Disease
Hemochromatosis
COMPLETED
Interest of Reticulocyte Haemoglobin Content (RET-he) in Management of Functional Anemia for Patient With Solid Tumor
NCT03656172
Solid Tumor, Adult
Anemia Deficiency
COMPLETED
Treatment of Hemochromatosis
NCT00007150
Hemochromatosis
ACTIVE_NOT_RECRUITING
PHASE2
Quality and Biologic Characteristics of Red Blood Concentrates Obtained From Individuals With Elevated Ferritin.
NCT05742035
Hereditary Hemochromatosis
Hyperferritinemia
UNKNOWN
NA
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Ferritin is a ubiquitous protein capable of storing iron in the cell cytosol. Cytosolic ferritin consists of two subunits, the light chain (L-ferritin) and the heavy chain (H-ferritin) that assemble in different proportions to form apo-ferritin shells. Ferritin nanoshells consist of 24 subunits of the L- and H-chains that create a cavity in which intracellular iron is collected. The stored iron is released and made available for cellular needs by the degradation of ferritin. Ferritin can bind, oxidize, and store up to 4500 Fe(II) atoms, preventing iron-mediated oxidative stress. This is achieved by regulating ferritin synthesis according to cellular iron content and oxidative stress at both the post-transcriptional (via the Iron Responsive Element (IRE)-regulatory protein (IRP) system) and transcriptional levels. Small amounts of ferritin are present in the blood and consist of ferritin L, a glycosylated form of L called ferritin G, and traces of ferritin H. It is secreted primarily by macrophages, hepatocytes, and lymphoid cells, but most aspects of its secretion remain unknown. Serum ferritin has broad clinical utility primarily as an indicator of intracellular iron stores.
The causes of increased serum ferritin are numerous, including primary and secondary iron overload disorders, but also conditions in which serum ferritin is increased disproportionately to the body's iron stores such as chronic liver disease, inflammatory and metabolic disorders that are frequently observed in the clinical setting. Therefore, the diagnosis of hyperferritinemia requires a systematic strategy including personal and family history, biochemical and instrumental tests. In addition, alterations in the regulation of ferritin synthesis due to mutations in the iron-sensitive element L-ferritin (IRE) cause hereditary hyperferritinemia cataract syndrome (HHCS), an inherited disease characterized by elevated serum ferritin without iron overload and early onset of bilateral cataracts. Recently, a second dominant form of genetic hyperferritinemia without iron overload or cataract has been reported. Amino acid substitutions at positions 26, 27, and 30 in the heterozygous state in the L-ferritin A helix have been found in these patients. The resulting ferritin appears unusually susceptible to glycosylation, leading to serum glycosylated ferritin values consistently \>90%. The reason for the development of hyperferritinemia and hyperglycosylation associated with these mutant forms of ferritin has not been established. It is probably related to increased secretion, but may also contribute to delayed clearance. Some cases of hyperferritinemia still remain unexplained, and the currently unknown candidate gene that we think we have identified among candidate genes needs to be validated in a larger population of subjects with the listed characteristics.
The primary objective of the study is to sequence the candidate gene that emerged from previous studies as mutated in patients with the same clinical features.
The secondary objective is to include the candidate gene in the routine genetic diagnosis of subjects with hyperferritinemia without tissue iron overload.
The study will last about 12 months the time needed for the recovery of patients with a genetic diagnosis not yet defined, analysis of medical records and research of the DNA sample stored at the Laboratory of Cytogenetics and Medical Genetics of San Gerardo Hospital and genetic analysis by Next Generation Sequencing. The study, although simple in its idea, requires a very careful organization of access and monitoring of selected patients that require the presence of a study manager dedicated to the project.
The study extension includes:glycosylated ferritin assay in patients with hyperferritinemia referred to the Rare Disease Center of IRCCS Foundation - San Gerardo dei Tintori selected according to the inclusion and exclusion criteria; soluble protein assay encoded by the STAB1 gene in patients in point A and patients in group D.
The causes of increased serum ferritin are numerous, including primary and secondary iron overload disorders, but also conditions in which serum ferritin is increased disproportionately to the body's iron stores such as chronic liver disease, inflammatory and metabolic disorders that are frequently observed in the clinical setting. Therefore, the diagnosis of hyperferritinemia requires a systematic strategy including personal and family history, biochemical and instrumental tests. In addition, alterations in the regulation of ferritin synthesis due to mutations in the iron-sensitive element L-ferritin (IRE) cause hereditary hyperferritinemia cataract syndrome (HHCS), an inherited disease characterized by elevated serum ferritin without iron overload and early onset of bilateral cataracts. Recently, a second dominant form of genetic hyperferritinemia without iron overload or cataract has been reported. Amino acid substitutions at positions 26, 27, and 30 in the heterozygous state in the L-ferritin A helix have been found in these patients. The resulting ferritin appears unusually susceptible to glycosylation, leading to serum glycosylated ferritin values consistently \>90%. The reason for the development of hyperferritinemia and hyperglycosylation associated with these mutant forms of ferritin has not been established. It is probably related to increased secretion, but may also contribute to delayed clearance. Some cases of hyperferritinemia still remain unexplained, and the currently unknown candidate gene that we think we have identified among candidate genes needs to be validated in a larger population of subjects with the listed characteristics.
The primary objective of the study is to sequence the candidate gene that emerged from previous studies as mutated in patients with the same clinical features.
The secondary objective is to include the candidate gene in the routine genetic diagnosis of subjects with hyperferritinemia without tissue iron overload.
The study will last about 12 months the time needed for the recovery of patients with a genetic diagnosis not yet defined, analysis of medical records and research of the DNA sample stored at the Laboratory of Cytogenetics and Medical Genetics of San Gerardo Hospital and genetic analysis by Next Generation Sequencing. The study, although simple in its idea, requires a very careful organization of access and monitoring of selected patients that require the presence of a study manager dedicated to the project.
The study extension includes:glycosylated ferritin assay in patients with hyperferritinemia referred to the Rare Disease Center of IRCCS Foundation - San Gerardo dei Tintori selected according to the inclusion and exclusion criteria; soluble protein assay encoded by the STAB1 gene in patients in point A and patients in group D.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Hyperferritinemia
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
Observational Model Type
COHORT
Study Time Perspective
RETROSPECTIVE
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Genetic analysis
The DNA will then be analyzed with a custom panel designed ad hoc to study the candidate gene by Next Generation Sequencing according to the protocols of the supplier of the kit.
Intervention Type
GENETIC
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Among patients referred to the Center for Rare Diseases of Monza will be enrolled only subjects with:
* ferritin \> 1000 g / L in men and \> 500 g / L,
* transferrin saturation \<45%
* absence of hepatic iron overload, evaluated by liver biopsy or MRI, as indicated in the attached flow chart.
* ferritin \> 1000 g / L in men and \> 500 g / L,
* transferrin saturation \<45%
* absence of hepatic iron overload, evaluated by liver biopsy or MRI, as indicated in the attached flow chart.
Exclusion Criteria
Patients with hyperferritinemia attributable to:
* genetically determined causes \[mutations in the HFE gene (homozygosity or heterozygosity for p.Cys282Tyr, homozygosity for p.His63Asp or compound heterozygosity for variants of p.Cys282Tyr and p. His63Asp), ferroportin and L-Ferritin gene mutations\];
* presence of more than one component of metabolic syndrome (according to NCEP-ATPIII criteria: triglycerides \>150 mg/dL, blood glucose \>100 mg/dL, HDL \<40 mg/dL in men and \<50 mg/dL in women, waist circumference \>102 cm in men and \>88 cm in women; blood pressure ≥130/≥85 mm/Hg);
* alcohol intake \>5 g/day chronic hepatitis,
* history of blood transfusion or parenteral iron treatment,
* late skin porphyria,
* hyperthyroidism,
* presence of cataracts or family history of early-onset cataracts
* acute or chronic inflammatory disorders.
* genetically determined causes \[mutations in the HFE gene (homozygosity or heterozygosity for p.Cys282Tyr, homozygosity for p.His63Asp or compound heterozygosity for variants of p.Cys282Tyr and p. His63Asp), ferroportin and L-Ferritin gene mutations\];
* presence of more than one component of metabolic syndrome (according to NCEP-ATPIII criteria: triglycerides \>150 mg/dL, blood glucose \>100 mg/dL, HDL \<40 mg/dL in men and \<50 mg/dL in women, waist circumference \>102 cm in men and \>88 cm in women; blood pressure ≥130/≥85 mm/Hg);
* alcohol intake \>5 g/day chronic hepatitis,
* history of blood transfusion or parenteral iron treatment,
* late skin porphyria,
* hyperthyroidism,
* presence of cataracts or family history of early-onset cataracts
* acute or chronic inflammatory disorders.
Minimum Eligible Age
18 Years
Maximum Eligible Age
80 Years
Eligible Sex
ALL
Accepts Healthy Volunteers
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
University of Milano Bicocca
OTHER
Sponsor Role
lead
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Sara Pelucchi
Principal Investigator
Responsibility Role
PRINCIPAL_INVESTIGATOR
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Centre for Rare Disease - Disorders of Iron Metabolism, ASST-Monza, San Gerardo Hospital, European Reference Network - EuroBloodNet
Monza, MB, Italy
Site Status
RECRUITING
Countries
Review the countries where the study has at least one active or historical site.
Italy
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
References
Explore related publications, articles, or registry entries linked to this study.
Arosio P, Levi S. Cytosolic and mitochondrial ferritins in the regulation of cellular iron homeostasis and oxidative damage. Biochim Biophys Acta. 2010 Aug;1800(8):783-92. doi: 10.1016/j.bbagen.2010.02.005. Epub 2010 Feb 20.
Reference Type
RESULT
Torti FM, Torti SV. Regulation of ferritin genes and protein. Blood. 2002 May 15;99(10):3505-16. doi: 10.1182/blood.v99.10.3505. No abstract available.
Reference Type
RESULT
Finazzi D, Arosio P. Biology of ferritin in mammals: an update on iron storage, oxidative damage and neurodegeneration. Arch Toxicol. 2014 Oct;88(10):1787-802. doi: 10.1007/s00204-014-1329-0. Epub 2014 Aug 15.
Reference Type
RESULT
Wang J, Pantopoulos K. Regulation of cellular iron metabolism. Biochem J. 2011 Mar 15;434(3):365-81. doi: 10.1042/BJ20101825.
Reference Type
RESULT
Cragg SJ, Wagstaff M, Worwood M. Sialic acid and the microheterogeneity of human serum ferritin. Clin Sci (Lond). 1980 Mar;58(3):259-62. doi: 10.1042/cs0580259.
Reference Type
RESULT
Santambrogio P, Cozzi A, Levi S, Arosio P. Human serum ferritin G-peptide is recognized by anti-L ferritin subunit antibodies and concanavalin-A. Br J Haematol. 1987 Feb;65(2):235-7. doi: 10.1111/j.1365-2141.1987.tb02271.x.
Reference Type
RESULT
Cohen LA, Gutierrez L, Weiss A, Leichtmann-Bardoogo Y, Zhang DL, Crooks DR, Sougrat R, Morgenstern A, Galy B, Hentze MW, Lazaro FJ, Rouault TA, Meyron-Holtz EG. Serum ferritin is derived primarily from macrophages through a nonclassical secretory pathway. Blood. 2010 Sep 2;116(9):1574-84. doi: 10.1182/blood-2009-11-253815. Epub 2010 May 14.
Reference Type
RESULT
Mack U, Cooksley WG, Ferris RA, Powell LW, Halliday JW. Regulation of plasma ferritin by the isolated perfused rat liver. Br J Haematol. 1981 Mar;47(3):403-12. doi: 10.1111/j.1365-2141.1981.tb02808.x.
Reference Type
RESULT
Tran TN, Eubanks SK, Schaffer KJ, Zhou CY, Linder MC. Secretion of ferritin by rat hepatoma cells and its regulation by inflammatory cytokines and iron. Blood. 1997 Dec 15;90(12):4979-86.
Reference Type
RESULT
Dorner MH, Silverstone A, Nishiya K, de Sostoa A, Munn G, de Sousa M. Ferritin synthesis by human T lymphocytes. Science. 1980 Aug 29;209(4460):1019-21. doi: 10.1126/science.6967622.
Reference Type
RESULT
Byg KE, Milman N, Hansen S, Agger AO. Serum Ferritin is a Reliable, Non-invasive Test for Iron Status in Pregnancy: Comparison of Ferritin with Other Iron Status Markers in a Longitudinal Study on Healthy Pregnant Women; Erythropoiesis. Hematology. 2000;5(4):319-325. doi: 10.1080/10245332.2000.11746526.
Reference Type
RESULT
Harrison PM, Arosio P. The ferritins: molecular properties, iron storage function and cellular regulation. Biochim Biophys Acta. 1996 Jul 31;1275(3):161-203. doi: 10.1016/0005-2728(96)00022-9.
Reference Type
RESULT
Jacobs A, Worwood M. Ferritin in serum. Clinical and biochemical implications. N Engl J Med. 1975 May 1;292(18):951-6. doi: 10.1056/NEJM197505012921805. No abstract available.
Reference Type
RESULT
Chen TT, Li L, Chung DH, Allen CD, Torti SV, Torti FM, Cyster JG, Chen CY, Brodsky FM, Niemi EC, Nakamura MC, Seaman WE, Daws MR. TIM-2 is expressed on B cells and in liver and kidney and is a receptor for H-ferritin endocytosis. J Exp Med. 2005 Oct 3;202(7):955-65. doi: 10.1084/jem.20042433.
Reference Type
RESULT
Li JY, Paragas N, Ned RM, Qiu A, Viltard M, Leete T, Drexler IR, Chen X, Sanna-Cherchi S, Mohammed F, Williams D, Lin CS, Schmidt-Ott KM, Andrews NC, Barasch J. Scara5 is a ferritin receptor mediating non-transferrin iron delivery. Dev Cell. 2009 Jan;16(1):35-46. doi: 10.1016/j.devcel.2008.12.002.
Reference Type
RESULT
Ravasi G, Pelucchi S, Mariani R, Casati M, Greni F, Arosio C, Pelloni I, Majore S, Santambrogio P, Levi S, Piperno A. Unexplained isolated hyperferritinemia without iron overload. Am J Hematol. 2017 Apr;92(4):338-343. doi: 10.1002/ajh.24641. Epub 2017 Feb 7.
Reference Type
RESULT
Aguilar-Martinez P, Schved JF, Brissot P. The evaluation of hyperferritinemia: an updated strategy based on advances in detecting genetic abnormalities. Am J Gastroenterol. 2005 May;100(5):1185-94. doi: 10.1111/j.1572-0241.2005.40998.x.
Reference Type
RESULT
Camaschella C, Poggiali E. Towards explaining "unexplained hyperferritinemia". Haematologica. 2009 Mar;94(3):307-9. doi: 10.3324/haematol.2008.005405.
Reference Type
RESULT
Kannengiesser C, Jouanolle AM, Hetet G, Mosser A, Muzeau F, Henry D, Bardou-Jacquet E, Mornet M, Brissot P, Deugnier Y, Grandchamp B, Beaumont C. A new missense mutation in the L ferritin coding sequence associated with elevated levels of glycosylated ferritin in serum and absence of iron overload. Haematologica. 2009 Mar;94(3):335-9. doi: 10.3324/haematol.2008.000125. Epub 2009 Jan 27.
Reference Type
RESULT
Thurlow V, Vadher B, Bomford A, DeLord C, Kannengiesser C, Beaumont C, Grandchamp B. Two novel mutations in the L ferritin coding sequence associated with benign hyperferritinaemia unmasked by glycosylated ferritin assay. Ann Clin Biochem. 2012 May;49(Pt 3):302-5. doi: 10.1258/acb.2011.011229. Epub 2012 Apr 25.
Reference Type
RESULT
Piperno A. Molecular diagnosis of hemochromatosis. Expert Opin Med Diagn. 2013 Mar;7(2):161-77. doi: 10.1517/17530059.2013.763794. Epub 2013 Jan 23.
Reference Type
RESULT
Riva A, Trombini P, Mariani R, Salvioni A, Coletti S, Bonfadini S, Paolini V, Pozzi M, Facchetti R, Bovo G, Piperno A. Revaluation of clinical and histological criteria for diagnosis of dysmetabolic iron overload syndrome. World J Gastroenterol. 2008 Aug 14;14(30):4745-52. doi: 10.3748/wjg.14.4745.
Reference Type
RESULT
National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation. 2002 Dec 17;106(25):3143-421. No abstract available.
Reference Type
RESULT
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
HyFerr
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.
Ferritin as a Predictor for Anemia in Pregnancy
NCT03565198
UNKNOWN
Cohort of Patients With Rare Iron Overloads Excluding C282Y Homozygosity
NCT02619955
COMPLETED
Hemochromatosis--Genetic Prevalence and Penetrance
NCT00006312
COMPLETED
Relative Contributions of Red Cell Catabolism and Dietary Absorption to Fetal Iron Accretion During Pregnancy
NCT01588665
COMPLETED
The Iron Content of Ferritin in Serum and Urine of Children With High Serum Ferritin Levels
NCT03777904
TERMINATED
PTG-300 in Subjects With Hereditary Hemochromatosis
NCT04202965
COMPLETED
PHASE2
Lactoferrin With Ferrous Gluconate Versus Ferrous Gluconate in Treatment of Iron Deficiency Anemia During Pregnancy
NCT06252103
COMPLETED
PHASE4
Genes Influencing Iron Overload State
NCT01158794
COMPLETED
Transferrin Saturation Coefficient and Ferritinemia in Diagnosis of Iron Deficiency
NCT04139265
COMPLETED
Impact of Bloodletting on Iron Metabolism in Type 1 Hemochromatosis
NCT01810965
COMPLETED
NA
Utility of Fibroscan in Estimating Hepatic Iron Concentration
NCT02067130
UNKNOWN
NA
Investigation of Ferritin in Critically Ill Patients With Hemophagocytic Lymphohistiocytosis
NCT02854943
COMPLETED
POlycythemia, Proteins and ErYthropoiesis
NCT06905106
RECRUITING
Hemoglobin and Iron Recovery Study
NCT01555060
COMPLETED
PHASE2
Frequency and Impact of Iron Deficiency in Pain Clinic Patients
NCT06665516
COMPLETED
Genes-in-Action - Hepcidin Regulation of Iron Supplementation
NCT03341338
COMPLETED
Cardiac Function in Patients With Hereditary Hemochromatosis
NCT00068159
COMPLETED
Different Iron Supplements for Prevention of Anemia in Pregnancy
NCT02487719
UNKNOWN
PHASE4
Phenotypic and Transcriptomic Description of Megakaryocytes in Sickle Cell Patient
NCT06887907
RECRUITING
Iron Depletion and Replacement in Blood Donors
NCT01752413
COMPLETED
NA
Study of the Role of Genetic Modifiers in Hemoglobinopathies
NCT05799118
RECRUITING
Iron Balance Study of DFO and GT56-252 in Patients With Transfusional Iron Overload Secondary to Beta-Thalassemia
NCT00069862
COMPLETED
PHASE1/PHASE2
Screening for Alpha Thalassemia in Healthy Volunteers
NCT02692872
ACTIVE_NOT_RECRUITING
Open-Label Study of Oral CEP-701 (Lestaurtinib) in Patients With Polycythemia Vera or Essential Thrombocytosis
NCT00586651
COMPLETED
PHASE2